-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12th, Buchang Pharmaceutical issued an announcement regarding the establishment of a holding subsidiary with foreign investment
.
The announcement shows that Buchang Pharmaceuticals will cooperate with other parties to invest in the establishment of Ningbo Buchang Trading Company
.
The newly established company belongs to the field of daily chemicals, and its business scope is the sale of toothpaste, soap, synthetic detergent, disinfection products, health care products, oral cleaners, other oral and toothpaste cleaners; self-operating and agency sales of various products and technologies exports of cosmetics and other domestic business, material supply and marketing industry; bath products, shampoos, bath salts and other Japanese goods purchase and sale
.
According to the data, Buchang Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines.
The main products involve the field of Chinese patent medicines for cardiovascular and cerebrovascular diseases, as well as other fields such as gynecological medicines
.
As a traditional Chinese medicine company, it has a cross-border layout of daily chemical products.
The analysis suggests that it may be related to the stricter control of traditional Chinese medicine in recent years.
In order to find new drivers for performance growth, Chinese medicine companies have chosen to deploy daily chemical industry
.
Prior to this, pharmaceutical companies including Jiuzhitang and Pien Tze Huang have set foot in the field of daily chemicals, creating traditional Chinese medicine oral products, Chinese medicine cosmetics, and Chinese medicine detergents
.
It is worth mentioning that Buchang Pharmaceuticals has implemented "switching from a sales company to a technology company", "switching from proprietary Chinese medicines to biological medicines, vaccines, chemical medicines, medical devices, and Internet medicines", and "switching from Chinese localization to technology companies.
" The three major transformation strategies of "Globalization Conversion", in addition to daily chemicals, have now been involved in many fields such as biomedicine, vaccines, and Internet medical treatment
.
Among them, in the field of biopharmaceuticals, in 2020, Buchang Pharmaceuticals has 10 therapeutic biological products and 2 preventive biological products (vaccine) under development.
Some products have entered clinical phase II or phase III, covering tumors and osteoporosis.
, Anemia, arthritis, cardiovascular and cerebrovascular areas
.
However, a product has not yet been launched on the market
.
In recent years, in the high-prosperity medical device field and Internet medical field, Buchang Pharmaceuticals is also taking advantage of the momentum to improve the strategic layout of the big health industry chain.
.
For example, in the first half of 2021, it will invest in the establishment of Buchang Tao Yiyun Health Technology (Hangzhou) Co.
, Ltd.
and Shangzhi Buchang Biomedical Technology Co.
, Ltd.
, and plan to invest in Jiangxi Buchang Mobile Medical Equipment Co.
, Ltd.
and Shangzhi Buchang Mobile Medical Equipment Co.
, Ltd.
Company
.
Some analysts believe that Buchang Pharmaceutical's "fancy" pace on the road of transformation may be related to the continuous decline in net profit growth
.
In recent years, the company’s leading products such as compound brain peptide ganglioside injection and Guhong injection have been transferred to medical insurance catalogs in many places.
Traditional Chinese medicine injections including Danhong injection have been included in the key monitoring drug catalogs by many provinces.
It has been warned (strictly monitored) and restricted for many times, and faces the risk of deactivation
.
Under the influence of these factors, the company's product sales will be hit, and it will have a greater impact on business performance
.
Financial data show that in 2018, 2019, 2020 and the first half of 2021, Buchang Pharmaceutical's net profit growth rate was 15.
29%, 3.
05%, -4.
37%, and 4.
98%, respectively
.
In addition, from the perspective of sales expenses, the company's sales expenses have remained high in recent years.
The 2020 annual report shows that its "marketing, academic promotion and consulting fees" amounted to 8.
028 billion yuan.
This data has also caused controversy in the industry
.
.
The announcement shows that Buchang Pharmaceuticals will cooperate with other parties to invest in the establishment of Ningbo Buchang Trading Company
.
The newly established company belongs to the field of daily chemicals, and its business scope is the sale of toothpaste, soap, synthetic detergent, disinfection products, health care products, oral cleaners, other oral and toothpaste cleaners; self-operating and agency sales of various products and technologies exports of cosmetics and other domestic business, material supply and marketing industry; bath products, shampoos, bath salts and other Japanese goods purchase and sale
.
According to the data, Buchang Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines.
The main products involve the field of Chinese patent medicines for cardiovascular and cerebrovascular diseases, as well as other fields such as gynecological medicines
.
As a traditional Chinese medicine company, it has a cross-border layout of daily chemical products.
The analysis suggests that it may be related to the stricter control of traditional Chinese medicine in recent years.
In order to find new drivers for performance growth, Chinese medicine companies have chosen to deploy daily chemical industry
.
Prior to this, pharmaceutical companies including Jiuzhitang and Pien Tze Huang have set foot in the field of daily chemicals, creating traditional Chinese medicine oral products, Chinese medicine cosmetics, and Chinese medicine detergents
.
It is worth mentioning that Buchang Pharmaceuticals has implemented "switching from a sales company to a technology company", "switching from proprietary Chinese medicines to biological medicines, vaccines, chemical medicines, medical devices, and Internet medicines", and "switching from Chinese localization to technology companies.
" The three major transformation strategies of "Globalization Conversion", in addition to daily chemicals, have now been involved in many fields such as biomedicine, vaccines, and Internet medical treatment
.
Among them, in the field of biopharmaceuticals, in 2020, Buchang Pharmaceuticals has 10 therapeutic biological products and 2 preventive biological products (vaccine) under development.
Some products have entered clinical phase II or phase III, covering tumors and osteoporosis.
, Anemia, arthritis, cardiovascular and cerebrovascular areas
.
However, a product has not yet been launched on the market
.
In recent years, in the high-prosperity medical device field and Internet medical field, Buchang Pharmaceuticals is also taking advantage of the momentum to improve the strategic layout of the big health industry chain.
.
For example, in the first half of 2021, it will invest in the establishment of Buchang Tao Yiyun Health Technology (Hangzhou) Co.
, Ltd.
and Shangzhi Buchang Biomedical Technology Co.
, Ltd.
, and plan to invest in Jiangxi Buchang Mobile Medical Equipment Co.
, Ltd.
and Shangzhi Buchang Mobile Medical Equipment Co.
, Ltd.
Company
.
Some analysts believe that Buchang Pharmaceutical's "fancy" pace on the road of transformation may be related to the continuous decline in net profit growth
.
In recent years, the company’s leading products such as compound brain peptide ganglioside injection and Guhong injection have been transferred to medical insurance catalogs in many places.
Traditional Chinese medicine injections including Danhong injection have been included in the key monitoring drug catalogs by many provinces.
It has been warned (strictly monitored) and restricted for many times, and faces the risk of deactivation
.
Under the influence of these factors, the company's product sales will be hit, and it will have a greater impact on business performance
.
Financial data show that in 2018, 2019, 2020 and the first half of 2021, Buchang Pharmaceutical's net profit growth rate was 15.
29%, 3.
05%, -4.
37%, and 4.
98%, respectively
.
In addition, from the perspective of sales expenses, the company's sales expenses have remained high in recent years.
The 2020 annual report shows that its "marketing, academic promotion and consulting fees" amounted to 8.
028 billion yuan.
This data has also caused controversy in the industry
.
